Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.35 |
| ▸ | PIK3C3 | Q8NEB9 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | GCK | P35557 | 2/20 | 0.34 |
| ▸ | GCKR | Q14397 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.32 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198944 | 0.78 | L3MBTL1 (0.34) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL20175445 | 0.78 | HCAR2 (0.40) | KDM4EHCAR2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL15865702 | 0.76 | HCAR2 (0.45) | CA1CA2CA12CA9KDM4E | |
| Hydrochloric Acid SCHEMBL28145192 | 0.74 | HCAR2 (0.44) | KDM4EHCAR2 | |
| SCHEMBL10442133 | 0.74 | NPC1 (0.39) | KDM4EHCAR2PIK3CDPIK3CBPIK3CG | |
| SCHEMBL10442596 | 0.73 | HCAR2 (0.46) | HCAR2PIK3CDPIK3CBPIK3CGPIK3C3 | |
| SCHEMBL4198555 | 0.72 | KDM4E (0.63) | KDM4EPOLBMAPTPFKFB3PFKFB4 | |
| SCHEMBL7082340 | 0.71 | MAPT (0.39) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL5228998 | 0.70 | PFKFB3 (0.55) | CA1CA2CA12CA9KDM4E | |
| SCHEMBL4491981 | 0.69 | MAPT (0.41) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122538-B2 | Sulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2006-10-17 | — | — | US | claimed |
| EP-1549639-B1 | SULPHONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LTD (GB) | 2006-05-24 | — | — | EP | claimed |
| US-20060063757-A1 | Sulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2006-03-23 | — | — | US | claimed |
| EP-1549639-A1 | SULPHONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | claimed |
| WO-2004031181-A1 | SULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2004-04-15 | — | — | WO | claimed |
| US-20100273849-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | US | disclosed |
| EP-1370537-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-10-13 | — | — | EP | disclosed |
| US-7666892-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2010-02-23 | — | — | US | disclosed |
| US-20080262045-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
| US-7368465-B2 | Respiratory system disorders; antiarthritic agents; anticancer agents; bone disorders | ASTRAZENECA AB (SE) | 2008-05-06 | — | — | US | disclosed |
| US-7122538-B2 | Sulfonamide derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2006-10-17 | — | — | US | disclosed |
| EP-1549639-B1 | SULPHONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LTD (GB) | 2006-05-24 | — | — | EP | disclosed |
| EP-1549639-A1 | SULPHONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-07-06 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040138276-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| WO-2004031181-A1 | SULFONAMIDE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370537-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074751-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273849-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | CA1 246/4885CA2 139/4885CA12 133/4885 |
| US-20080262045-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP11 | CA1 246/4885CA2 139/4885CA12 133/4885 |
| US-20060063757-A1 | Sulfonamide derivatives as antipsychotic agents | SIGMAR1, CHRM1, NPSR1 | CA1 175/4885CA2 598/4885CA12 811/4885 |
| US-20040138276-A1 | Metalloproteinase inhibitors | MMP9, MMP11, MMP7 | CA1 335/4885CA2 199/4885CA12 257/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | CA1 134/4885CA2 146/4885CA12 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.